79567-66-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-benzoylpyridine is utilized as an intermediate in the synthesis of various pharmaceutical products, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
As a building block in organic synthesis, 2-Chloro-5-benzoylpyridine can be employed to create a range of different pyridine derivatives, expanding the scope of chemical compounds available for research and application.
Used in Medicinal Chemistry and Drug Discovery:
Possessing potential biological activity, 2-Chloro-5-benzoylpyridine may have applications in medicinal chemistry and drug discovery, offering a foundation for the creation of novel compounds with therapeutic potential.

InChI:InChI=1/C12H8ClNO/c13-11-7-6-10(8-14-11)12(15)9-4-2-1-3-5-9/h1-8H

Upstream product

• 58757-38-3 6-Chloronicotinoyl chloride 
• 71-43-2 benzene 
• 100-59-4 phenylmagnesium chloride 
• 727409-19-0 (6-chloro-3-pyridinyl)(oxo)acetonitrile 
• 591-51-5 phenyllithium 
• 149281-42-5 6-chloro-N-methoxy-N-methylpyridine-3-carboxamide 

Downstream Products

• 929918-49-0 (S)-2-(5-Benzoyl-pyridin-2-yloxymethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 53439-80-8 2-amino-5-benzoylpyridine 
• 276673-94-0 4-[3-(5-phenylcarbonyl-pyrid-2-yl)-propargylamino]benzamidine 
• 79567-64-9 (6-Benzoyl-imidazo[1,2-a]pyridin-2-yl)-carbamic acid methyl ester 
• 220259-98-3 2-trifluoroacetamido-3-(2,3,4-trifluorophenyl)-6-<(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl>imidazo<1,2-a>pyridine 
• 220259-99-4 2-trifluoroacetamido-3-(3-trifluoromethylphenyl)-6-<(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl>imidazo<1,2-a>pyridine 
• 220259-88-1 1,2-dihydro-2-p-toluenesulfonimido-5-benzoyl-N-<1-(2-trifluoromethyl-4-fluorophenyl)carbamoylmethyl>pyridine 
• 220259-97-2 2-trifluoroacetamido-3-(2,5-difluorophenyl)-6-<(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl>imidazo<1,2-a>pyridine 
• 220259-86-9 1,2-dihydro-2-p-toluenesulfonimido-5-benzoyl-N-<1-(2,3,4-trifluorophenyl)carbamoylmethyl>pyridine 
• 220259-87-0 1,2-dihydro-2-p-toluenesulfonimido-5-benzoyl-N-<1-(3-trifluoromethylphenyl)carbamoylmethyl>pyridine 
• 220259-94-9 2-trifluoroacetamido-3-(2-trifluoromethyl-4-fluorophenyl)-6-benzoylimidazo<1,2-a>pyridine 
• 220259-85-8 1,2-dihydro-2-p-toluenesulfonimido-5-benzoyl-N-<1-(2,5-difluorophenyl)carbamoylmethyl>pyridine 
• 220259-92-7 2-trifluoroacetamido-3-(2,3,4-trifluorophenyl)-6-benzoylimidazo<1,2-a>pyridine 
• 220259-93-8 2-trifluoroacetamido-3-(3-trifluoromethylphenyl)-6-benzoylimidazo<1,2-a>pyridine 

Relevant academic research and scientific papers

COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA

The invention provides compounds of formula (I), their pharmaceutically acceptable salts and prodrugs thereof for use in preventing, inhibiting or treating a disease caused by a mutation in the gene coding for hydroxymethylbilane synthase, in particular f

BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION

The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is

Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation

Synthesis of 2-aminoimidazo[1,2-a]pyridines 1 and their evaluation as CDK2 inhibitors is described. We have identified a novel structural class of protein serine/threonine kinase inhibitors comprised of an aminoimidazo[1,2-a]pyridine nucleus. Compounds from this family are shown to potently inhibit cyclin-dependent kinases by competing with ATP for binding to a catalytic subunit of the protein. Structure-based design approach was used to direct this chemical scaffold toward generating potent and selective CDK2 inhibitors. The discovery of this new class of ATP-site directed protein kinase inhibitors, aminoimidazo[1,2-a]pyridines, provides the basis of new medicinal chemistry tool in search for an effective treatment of cancer and other diseases that involve protein kinase signaling pathways.

An efficient synthesis of diaryl ketones by iron-catalyzed arylation of aroyl cyanides

An alternative to acyl chlorides: Iron(III)-catalyzed arylation of aroyl and heteroaroyl cyanides with aryl magnesium reagents (see example in scheme) provides an easy and mild approach to polyfunctionalized diaryl ketones in yields up to 98%.

Anti-viral compounds

The present invention relates to compounds of Formula (I) below, which inhibit the growth of picornaviruses, Hepatitus viruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus. wherein: A is phenyl, pyridyl, substituted phenyl, substituted pyridyl, or benzyl; R is hydrogen, COR4, or COCF3; X is N—OH, O, or CHR1; R1is hydrogen, halo, CN, C1-C4alkyl, —C≡CH, CO(C1-C4alkyl), CO2(C1-C4alkyl), or CONR2R3; R2and R3are independently hydrogen or C1-C4alkyl; A′ is hydrogen, halo, C1-C6alkyl, benzyl, naphthyl, thienyl, furyl, pyridyl, pyrollyl, COR4, S(O)nR4, or a group of the formula R4is C1-C6alkyl, phenyl, or substituted phenyl; n is 0, 1, or 2; R5is independently at each occurrence hydrogen or halo; m is 1, 2, 3, or 4; and R6is hydrogen, halo, CF3, OH, CO2H, NH2, NO2, CONHOCH3, C1-C4alkyl, or CO2(C1-C4alkyl), C1-C4alkoxy; or a pharmaceutically acceptable salt thereof.

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

Structure-activity relationship studies on 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase

Leukotriene B4 (LTB4) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA4 hydrolase is the rate-limiting step for LTB4 production, this enzyme represents an attractive pharmacological target for the suppression of LTB4 production. From an in- house screening program, SC-22716 (1, 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA4 hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA4 hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.

2-amino-3-substituted-6-[(E)-1-phenyl-2-(N- methylcarbamoyl)vinyl]imidazo-[1,2-a]pyridines as a novel class of inhibitors of human rhinovirus: Stereospecific synthesis and antiviral activity

A series of 2-amino-3-substituted-6-[(E)-1-phenyl-2-(N- methylcarbamoyl)vinyl]imidazo[1,2-a]-pyridines 1a-i, structurally related to Enviroxime and its analogous benzimidazoles, was designed and prepared for testing as antirhinovirus agents. The imidazo ring in this class of compounds was constructed starting from the aminopyridine after tosylation and subsequent treatment with the appropriate acetamides. The key steps in the synthesis include the development and use of a new Horner-Emmons reagent for the direct incorporation of methyl vinylcarboxamide. The reaction was stereospecific in the substrates 5a-f leading exclusively to the desired E- isomer and avoiding the use of reverse-phase preparative HPLC for the separation of both possible isomers before antiviral activity evaluation. The isopropylsulfonyl group, known as the best substituent at the 1-position in the benzimidazole SAR in terms of activity, was introduced in this new series of imidazo[1,2-a]pyridines via halogen-metal exchange and subsequent treatment with isopropyl isopropanethiolsulfonate. Compounds 1a-i were evaluated in plaque reduction assay and in a cytopathic effect assay. Compounds 1b-d,h exhibited a strong antirhinovirus activity, and no apparent cellular toxicity was visible. The substitution at the 3-position was required for activity. Surprisingly the isopropylsulfonyl in this family of compounds did not enhance the activity as in the case of benzimidazoles. Instead, compound 1i was 4 times less active than its phenyl and sulfide partners. The chemistry as well as the biological evaluation are discussed.

2-aryl-2-(3-pyridyl)-1,3-dioxalanes, dithiolanes and -oxa-thiolanes having herbicidal and pesticidal activity

Fungicidal and herbicidal novel 3-substituted pyridines of the formula STR1 wherein A represents oxygen or sulfur, B represents oxygen, sulfur or sulfinyl, R1 represents hydrogen, halogen, alkyl or haloalkyl, R2 represents hydrogen,

Fungicidal 2-(-3-pyridyl)-1,3-dioxanes

Fungicidal and herbicidal novel 3-substituted pyridines of the formula STR1 wherein A represents oxygen or sulfur, B represents oxygen, sulfur or sulfinyl, R1 represents hydrogen, halogen, alkyl or haloalkyl, R2 represents hydrogen,